A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma
Identifieur interne : 001C58 ( Istex/Corpus ); précédent : 001C57; suivant : 001C59A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma
Auteurs : Keith J. Stelzer ; Thomas W. GriffinSource :
- International Journal of Radiation Oncology, Biology, Physics [ 0360-3016 ] ; 1993.
English descriptors
- Teeft :
- Acute toxicity, Aids patients, Anatomical location, Chemotherapy, Complete response, Cosmetic reasons, Crude incidence, Cutaneous, Cutaneous kaposi, Cytotoxic chemotherapy, Epidemic kaposi, Exact test, First manifestation, Good response, High performance status, Higher dose, Higher proportion, Immune deficiency syndrome, Individual lesions, Individual patients, Kaposi, Late toxicity, Lesion, Lesion characteristics, Lesion control, Lesion failure, Lesion size, Median, Median time, Objective response, Oncol, Other sites, Palpable tumor, Partial response, Patient performance status, Proportional differences, Protracted treatment course, Radiation dose, Radiation oncology, Radiation regimens, Radiation therapy, Radiotherapy, Randomized study, Regimen, Sarcoma, Single dose, Skin erythema, Toxicity, Treatment intent, Tumor control, Tumor response.
Abstract
Abstract: Purpose: The optimal dose of radiation in the treatment of AIDS-associated Kaposi's sarcoma has been controversial based on previous nonrandomized retrospective studies.Methods and Materials: Seventy-one cutaneous AIDS-associated Kaposi's sarcoma lesions were randomly assigned to 1 of 3 radiation dose regimens-8 Gy in 1 fraction, 20 Gy in 10 fraction. and 40 Gy in 20 fractions. Lesions were measured prior to and following treatment. Complete resolution of palpable tumor was considered a complete response, regardless of residual purple pigmentation. Reduction in palpable tumor to less than 50% of pretreatment area was considered an objective response. Less than 50% reduction in tumor size was considered a nonresponse.Results: Complete response was higher (p = .04) with 40 Gy (83%) and 20 Gy (79%) than with 8 Gy (50%). Absence of residual purple pigmentation was greater (p = .005) with 40 Gy (43%) than with 20 Gy (8%) or 8 Gy (8%). Lesion failure was lower (p = .03) with 40 Gy (52%) than with 20 Gy (67%) or 8 Gy (88%). Median time to failure was 43 weeks with 40 Gy, 26 weeks with 20 Gy, and 13 weeks with 8 Gy (p = .003).Conclusion: Fractionated radiotherapy to higher total doses resulted in improved response and control of cutaneous Kaposi's sarcoma. This dose-dependence should be considered in determining the optimal radiotherapeutic regimen for individual patients treated for epidemic Kaposi's sarcoma.
Url:
DOI: 10.1016/0360-3016(93)90523-X
Links to Exploration step
ISTEX:DDDCADE1BD5C73E76267EB6DCB1E821AD15A95C0Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma</title><author><name sortKey="Stelzer, Keith J" sort="Stelzer, Keith J" uniqKey="Stelzer K" first="Keith J." last="Stelzer">Keith J. Stelzer</name><affiliation><mods:affiliation>Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA</mods:affiliation></affiliation></author><author><name sortKey="Griffin, Thomas W" sort="Griffin, Thomas W" uniqKey="Griffin T" first="Thomas W." last="Griffin">Thomas W. Griffin</name><affiliation><mods:affiliation>Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DDDCADE1BD5C73E76267EB6DCB1E821AD15A95C0</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1016/0360-3016(93)90523-X</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-MMDNXDWP-W/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001C58</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001C58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma</title><author><name sortKey="Stelzer, Keith J" sort="Stelzer, Keith J" uniqKey="Stelzer K" first="Keith J." last="Stelzer">Keith J. Stelzer</name><affiliation><mods:affiliation>Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA</mods:affiliation></affiliation></author><author><name sortKey="Griffin, Thomas W" sort="Griffin, Thomas W" uniqKey="Griffin T" first="Thomas W." last="Griffin">Thomas W. Griffin</name><affiliation><mods:affiliation>Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">International Journal of Radiation Oncology, Biology, Physics</title><title level="j" type="abbrev">ROB</title><idno type="ISSN">0360-3016</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1993">1993</date><biblScope unit="volume">27</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="1057">1057</biblScope><biblScope unit="page" to="1061">1061</biblScope></imprint><idno type="ISSN">0360-3016</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0360-3016</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acute toxicity</term><term>Aids patients</term><term>Anatomical location</term><term>Chemotherapy</term><term>Complete response</term><term>Cosmetic reasons</term><term>Crude incidence</term><term>Cutaneous</term><term>Cutaneous kaposi</term><term>Cytotoxic chemotherapy</term><term>Epidemic kaposi</term><term>Exact test</term><term>First manifestation</term><term>Good response</term><term>High performance status</term><term>Higher dose</term><term>Higher proportion</term><term>Immune deficiency syndrome</term><term>Individual lesions</term><term>Individual patients</term><term>Kaposi</term><term>Late toxicity</term><term>Lesion</term><term>Lesion characteristics</term><term>Lesion control</term><term>Lesion failure</term><term>Lesion size</term><term>Median</term><term>Median time</term><term>Objective response</term><term>Oncol</term><term>Other sites</term><term>Palpable tumor</term><term>Partial response</term><term>Patient performance status</term><term>Proportional differences</term><term>Protracted treatment course</term><term>Radiation dose</term><term>Radiation oncology</term><term>Radiation regimens</term><term>Radiation therapy</term><term>Radiotherapy</term><term>Randomized study</term><term>Regimen</term><term>Sarcoma</term><term>Single dose</term><term>Skin erythema</term><term>Toxicity</term><term>Treatment intent</term><term>Tumor control</term><term>Tumor response</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Purpose: The optimal dose of radiation in the treatment of AIDS-associated Kaposi's sarcoma has been controversial based on previous nonrandomized retrospective studies.Methods and Materials: Seventy-one cutaneous AIDS-associated Kaposi's sarcoma lesions were randomly assigned to 1 of 3 radiation dose regimens-8 Gy in 1 fraction, 20 Gy in 10 fraction. and 40 Gy in 20 fractions. Lesions were measured prior to and following treatment. Complete resolution of palpable tumor was considered a complete response, regardless of residual purple pigmentation. Reduction in palpable tumor to less than 50% of pretreatment area was considered an objective response. Less than 50% reduction in tumor size was considered a nonresponse.Results: Complete response was higher (p = .04) with 40 Gy (83%) and 20 Gy (79%) than with 8 Gy (50%). Absence of residual purple pigmentation was greater (p = .005) with 40 Gy (43%) than with 20 Gy (8%) or 8 Gy (8%). Lesion failure was lower (p = .03) with 40 Gy (52%) than with 20 Gy (67%) or 8 Gy (88%). Median time to failure was 43 weeks with 40 Gy, 26 weeks with 20 Gy, and 13 weeks with 8 Gy (p = .003).Conclusion: Fractionated radiotherapy to higher total doses resulted in improved response and control of cutaneous Kaposi's sarcoma. This dose-dependence should be considered in determining the optimal radiotherapeutic regimen for individual patients treated for epidemic Kaposi's sarcoma.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>kaposi</json:string><json:string>toxicity</json:string><json:string>lesion</json:string><json:string>sarcoma</json:string><json:string>regimen</json:string><json:string>cutaneous</json:string><json:string>radiotherapy</json:string><json:string>chemotherapy</json:string><json:string>oncol</json:string><json:string>treatment intent</json:string><json:string>radiation therapy</json:string><json:string>single dose</json:string><json:string>palpable tumor</json:string><json:string>late toxicity</json:string><json:string>radiation regimens</json:string><json:string>median</json:string><json:string>tumor control</json:string><json:string>radiation oncology</json:string><json:string>anatomical location</json:string><json:string>lesion characteristics</json:string><json:string>tumor response</json:string><json:string>cytotoxic chemotherapy</json:string><json:string>individual lesions</json:string><json:string>complete response</json:string><json:string>lesion failure</json:string><json:string>epidemic kaposi</json:string><json:string>median time</json:string><json:string>immune deficiency syndrome</json:string><json:string>lesion size</json:string><json:string>aids patients</json:string><json:string>patient performance status</json:string><json:string>proportional differences</json:string><json:string>first manifestation</json:string><json:string>higher proportion</json:string><json:string>crude incidence</json:string><json:string>higher dose</json:string><json:string>cutaneous kaposi</json:string><json:string>radiation dose</json:string><json:string>skin erythema</json:string><json:string>partial response</json:string><json:string>exact test</json:string><json:string>acute toxicity</json:string><json:string>other sites</json:string><json:string>good response</json:string><json:string>individual patients</json:string><json:string>objective response</json:string><json:string>high performance status</json:string><json:string>cosmetic reasons</json:string><json:string>protracted treatment course</json:string><json:string>randomized study</json:string><json:string>lesion control</json:string></teeft></keywords><author><json:item><name>Keith J. Stelzer M.D., Ph.D.</name><affiliations><json:string>Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA</json:string></affiliations></json:item><json:item><name>Thomas W. Griffin M.D.</name><affiliations><json:string>Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Kaposi's sarcoma</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Radiation therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Acquired immune deficiency syndrome</value></json:item></subject><arkIstex>ark:/67375/6H6-MMDNXDWP-W</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: Purpose: The optimal dose of radiation in the treatment of AIDS-associated Kaposi's sarcoma has been controversial based on previous nonrandomized retrospective studies.Methods and Materials: Seventy-one cutaneous AIDS-associated Kaposi's sarcoma lesions were randomly assigned to 1 of 3 radiation dose regimens-8 Gy in 1 fraction, 20 Gy in 10 fraction. and 40 Gy in 20 fractions. Lesions were measured prior to and following treatment. Complete resolution of palpable tumor was considered a complete response, regardless of residual purple pigmentation. Reduction in palpable tumor to less than 50% of pretreatment area was considered an objective response. Less than 50% reduction in tumor size was considered a nonresponse.Results: Complete response was higher (p = .04) with 40 Gy (83%) and 20 Gy (79%) than with 8 Gy (50%). Absence of residual purple pigmentation was greater (p = .005) with 40 Gy (43%) than with 20 Gy (8%) or 8 Gy (8%). Lesion failure was lower (p = .03) with 40 Gy (52%) than with 20 Gy (67%) or 8 Gy (88%). Median time to failure was 43 weeks with 40 Gy, 26 weeks with 20 Gy, and 13 weeks with 8 Gy (p = .003).Conclusion: Fractionated radiotherapy to higher total doses resulted in improved response and control of cutaneous Kaposi's sarcoma. This dose-dependence should be considered in determining the optimal radiotherapeutic regimen for individual patients treated for epidemic Kaposi's sarcoma.</abstract><qualityIndicators><score>7.808</score><pdfWordCount>3072</pdfWordCount><pdfCharCount>19271</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>605 x 821 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>228</abstractWordCount><abstractCharCount>1435</abstractCharCount><keywordCount>3</keywordCount></qualityIndicators><title>A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma</title><pii><json:string>0360-3016(93)90523-X</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>International Journal of Radiation Oncology, Biology, Physics</title><language><json:string>unknown</json:string></language><publicationDate>1993</publicationDate><issn><json:string>0360-3016</json:string></issn><pii><json:string>S0360-3016(00)X0362-8</json:string></pii><volume>27</volume><issue>5</issue><pages><first>1057</first><last>1061</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1993</json:string><json:string>1987</json:string></date><geogName></geogName><orgName><json:string>Department PH</json:string><json:string>University of Washington Medical Center</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>GRIFFIN Table</json:string><json:string>Of</json:string></persName><placeName></placeName><ref_url></ref_url><ref_bibl><json:string>Cooper et al.</json:string><json:string>Berson et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-MMDNXDWP-W</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - radiology, nuclear medicine & medical imaging</json:string><json:string>2 - oncology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - oncology & carcinogenesis</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Cancer Research</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Radiology Nuclear Medicine and imaging</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Oncology</json:string><json:string>1 - Physical Sciences</json:string><json:string>2 - Physics and Astronomy</json:string><json:string>3 - Radiation</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1993</publicationDate><copyrightDate>1993</copyrightDate><doi><json:string>10.1016/0360-3016(93)90523-X</json:string></doi><id>DDDCADE1BD5C73E76267EB6DCB1E821AD15A95C0</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-MMDNXDWP-W/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-MMDNXDWP-W/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-MMDNXDWP-W/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1993</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Presented at the 75th Annual Meeting of the American Radium Society, Aruba, April 27, 1993.</note><note type="content">Section title: Clinical original contribution</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma</title><author xml:id="author-0000"><persName><forename type="first">Keith J.</forename><surname>Stelzer</surname></persName><roleName type="degree">M.D., Ph.D.</roleName><note type="biography">Reprint requests to: Keith J. Stelzer, M.D., Ph.D., Dept. of Radiation Oncology, University of Washington Medical Center, 1959 Pacific St., RC-08, Seattle, WA 98195.</note><affiliation>Reprint requests to: Keith J. Stelzer, M.D., Ph.D., Dept. of Radiation Oncology, University of Washington Medical Center, 1959 Pacific St., RC-08, Seattle, WA 98195.</affiliation><affiliation>Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Thomas W.</forename><surname>Griffin</surname></persName><roleName type="degree">M.D.</roleName><affiliation>Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA</affiliation></author><idno type="istex">DDDCADE1BD5C73E76267EB6DCB1E821AD15A95C0</idno><idno type="ark">ark:/67375/6H6-MMDNXDWP-W</idno><idno type="DOI">10.1016/0360-3016(93)90523-X</idno><idno type="PII">0360-3016(93)90523-X</idno></analytic><monogr><title level="j">International Journal of Radiation Oncology, Biology, Physics</title><title level="j" type="abbrev">ROB</title><idno type="pISSN">0360-3016</idno><idno type="PII">S0360-3016(00)X0362-8</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1993"></date><biblScope unit="volume">27</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="1057">1057</biblScope><biblScope unit="page" to="1061">1061</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1993</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Purpose: The optimal dose of radiation in the treatment of AIDS-associated Kaposi's sarcoma has been controversial based on previous nonrandomized retrospective studies.Methods and Materials: Seventy-one cutaneous AIDS-associated Kaposi's sarcoma lesions were randomly assigned to 1 of 3 radiation dose regimens-8 Gy in 1 fraction, 20 Gy in 10 fraction. and 40 Gy in 20 fractions. Lesions were measured prior to and following treatment. Complete resolution of palpable tumor was considered a complete response, regardless of residual purple pigmentation. Reduction in palpable tumor to less than 50% of pretreatment area was considered an objective response. Less than 50% reduction in tumor size was considered a nonresponse.Results: Complete response was higher (p = .04) with 40 Gy (83%) and 20 Gy (79%) than with 8 Gy (50%). Absence of residual purple pigmentation was greater (p = .005) with 40 Gy (43%) than with 20 Gy (8%) or 8 Gy (8%). Lesion failure was lower (p = .03) with 40 Gy (52%) than with 20 Gy (67%) or 8 Gy (88%). Median time to failure was 43 weeks with 40 Gy, 26 weeks with 20 Gy, and 13 weeks with 8 Gy (p = .003).Conclusion: Fractionated radiotherapy to higher total doses resulted in improved response and control of cutaneous Kaposi's sarcoma. This dose-dependence should be considered in determining the optimal radiotherapeutic regimen for individual patients treated for epidemic Kaposi's sarcoma.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Kaposi's sarcoma</term></item><item><term>Radiation therapy</term></item><item><term>Acquired immune deficiency syndrome</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1993">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-MMDNXDWP-W/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" </istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>ROB</jid><aid>9390523X</aid><ce:pii>0360-3016(93)90523-X</ce:pii><ce:doi>10.1016/0360-3016(93)90523-X</ce:doi><ce:copyright type="unknown" year="1993"></ce:copyright></item-info><head><ce:article-footnote><ce:label>☆</ce:label><ce:note-para>Presented at the 75th Annual Meeting of the American Radium Society, Aruba, April 27, 1993.</ce:note-para></ce:article-footnote><ce:dochead><ce:textfn>Clinical original contribution</ce:textfn></ce:dochead><ce:title>A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma</ce:title><ce:author-group><ce:author><ce:given-name>Keith J.</ce:given-name><ce:surname>Stelzer</ce:surname><ce:degrees>M.D., Ph.D.</ce:degrees><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Thomas W.</ce:given-name><ce:surname>Griffin</ce:surname><ce:degrees>M.D.</ce:degrees></ce:author><ce:affiliation><ce:textfn>Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Reprint requests to: Keith J. Stelzer, M.D., Ph.D., Dept. of Radiation Oncology, University of Washington Medical Center, 1959 Pacific St., RC-08, Seattle, WA 98195.</ce:text></ce:correspondence></ce:author-group><ce:date-accepted day="19" month="7" year="1993"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para><math altimg="si1.gif"><rm><unl type="bar">Purpose</unl></rm></math>: The optimal dose of radiation in the treatment of AIDS-associated Kaposi's sarcoma has been controversial based on previous nonrandomized retrospective studies.</ce:simple-para><ce:simple-para><math altimg="si2.gif"><rm><unl type="bar">Methods and Materials</unl></rm></math>: Seventy-one cutaneous AIDS-associated Kaposi's sarcoma lesions were randomly assigned to 1 of 3 radiation dose regimens-8 Gy in 1 fraction, 20 Gy in 10 fraction. and 40 Gy in 20 fractions. Lesions were measured prior to and following treatment. Complete resolution of palpable tumor was considered a complete response, regardless of residual purple pigmentation. Reduction in palpable tumor to less than 50% of pretreatment area was considered an objective response. Less than 50% reduction in tumor size was considered a nonresponse.</ce:simple-para><ce:simple-para><math altimg="si3.gif"><rm><unl type="bar">Results</unl></rm></math>: Complete response was higher (<ce:italic>p</ce:italic> = .04) with 40 Gy (83%) and 20 Gy (79%) than with 8 Gy (50%). Absence of residual purple pigmentation was greater (<ce:italic>p</ce:italic> = .005) with 40 Gy (43%) than with 20 Gy (8%) or 8 Gy (8%). Lesion failure was lower (<ce:italic>p</ce:italic> = .03) with 40 Gy (52%) than with 20 Gy (67%) or 8 Gy (88%). Median time to failure was 43 weeks with 40 Gy, 26 weeks with 20 Gy, and 13 weeks with 8 Gy (<ce:italic>p</ce:italic> = .003).</ce:simple-para><ce:simple-para><math altimg="si4.gif"><rm><unl type="bar">Conclusion</unl></rm></math>: Fractionated radiotherapy to higher total doses resulted in improved response and control of cutaneous Kaposi's sarcoma. This dose-dependence should be considered in determining the optimal radiotherapeutic regimen for individual patients treated for epidemic Kaposi's sarcoma.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Kaposi's sarcoma</ce:text></ce:keyword><ce:keyword><ce:text>Radiation therapy</ce:text></ce:keyword><ce:keyword><ce:text>Acquired immune deficiency syndrome</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma</title></titleInfo><name type="personal"><namePart type="given">Keith J.</namePart><namePart type="family">Stelzer</namePart><namePart type="termsOfAddress">M.D., Ph.D.</namePart><affiliation>Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA</affiliation><description>Reprint requests to: Keith J. Stelzer, M.D., Ph.D., Dept. of Radiation Oncology, University of Washington Medical Center, 1959 Pacific St., RC-08, Seattle, WA 98195.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thomas W.</namePart><namePart type="family">Griffin</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1993</dateIssued><copyrightDate encoding="w3cdtf">1993</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Purpose: The optimal dose of radiation in the treatment of AIDS-associated Kaposi's sarcoma has been controversial based on previous nonrandomized retrospective studies.Methods and Materials: Seventy-one cutaneous AIDS-associated Kaposi's sarcoma lesions were randomly assigned to 1 of 3 radiation dose regimens-8 Gy in 1 fraction, 20 Gy in 10 fraction. and 40 Gy in 20 fractions. Lesions were measured prior to and following treatment. Complete resolution of palpable tumor was considered a complete response, regardless of residual purple pigmentation. Reduction in palpable tumor to less than 50% of pretreatment area was considered an objective response. Less than 50% reduction in tumor size was considered a nonresponse.Results: Complete response was higher (p = .04) with 40 Gy (83%) and 20 Gy (79%) than with 8 Gy (50%). Absence of residual purple pigmentation was greater (p = .005) with 40 Gy (43%) than with 20 Gy (8%) or 8 Gy (8%). Lesion failure was lower (p = .03) with 40 Gy (52%) than with 20 Gy (67%) or 8 Gy (88%). Median time to failure was 43 weeks with 40 Gy, 26 weeks with 20 Gy, and 13 weeks with 8 Gy (p = .003).Conclusion: Fractionated radiotherapy to higher total doses resulted in improved response and control of cutaneous Kaposi's sarcoma. This dose-dependence should be considered in determining the optimal radiotherapeutic regimen for individual patients treated for epidemic Kaposi's sarcoma.</abstract><note>Presented at the 75th Annual Meeting of the American Radium Society, Aruba, April 27, 1993.</note><note type="content">Section title: Clinical original contribution</note><subject><genre>Keywords</genre><topic>Kaposi's sarcoma</topic><topic>Radiation therapy</topic><topic>Acquired immune deficiency syndrome</topic></subject><relatedItem type="host"><titleInfo><title>International Journal of Radiation Oncology, Biology, Physics</title></titleInfo><titleInfo type="abbreviated"><title>ROB</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1993</dateIssued></originInfo><identifier type="ISSN">0360-3016</identifier><identifier type="PII">S0360-3016(00)X0362-8</identifier><part><date>1993</date><detail type="volume"><number>27</number><caption>vol.</caption></detail><detail type="issue"><number>5</number><caption>no.</caption></detail><extent unit="issue-pages"><start>999</start><end>1260</end></extent><extent unit="pages"><start>1057</start><end>1061</end></extent></part></relatedItem><identifier type="istex">DDDCADE1BD5C73E76267EB6DCB1E821AD15A95C0</identifier><identifier type="ark">ark:/67375/6H6-MMDNXDWP-W</identifier><identifier type="DOI">10.1016/0360-3016(93)90523-X</identifier><identifier type="PII">0360-3016(93)90523-X</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-MMDNXDWP-W/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001C58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:DDDCADE1BD5C73E76267EB6DCB1E821AD15A95C0
|texte= A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma
}}
| This area was generated with Dilib version V0.6.33. |  |